ATSENA THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.atsenatx.com
Clinical Trials
2
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Atsena Therapeutics Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT05878860
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸Oregon Health Sciences University, Portland, Oregon, United States
Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Phase 1
Active, not recruiting
- Conditions
- LCALCA1Leber Congenital Amaurosis
- Interventions
- Drug: Triamcinalone AcetonideDrug: Trimethoprim/polymyxin B
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Atsena Therapeutics Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03920007
- Locations
- 🇺🇸
Casey Eye Institute - Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
News
No news found